Core Viewpoint - The announcement highlights that Sino Medical Technology Co., Ltd.'s subsidiary, Sino Shenchang Medical Technology Co., Ltd., has received EU CE MDR certification for its Ghunter intracranial thrombectomy stent, marking a significant milestone for the company in entering the European market [2][5]. Group 1: Certification Details - The Ghunter intracranial thrombectomy stent was registered under the EU Medical Devices Regulation (EU) 2017/745 and has received the EU CE MDR certification [2]. - The product is designed for the removal of thrombus in large vessels of ischemic stroke patients within 24 hours of symptom onset, and it is a single-use device with a shelf life of 2 years [3][4]. - The certification includes an EU Quality Management System Certificate and an EU Technical Documentation Assessment Certificate, with the certificate issued on February 18, 2026, and expiring on February 1, 2031 [4]. Group 2: Product Features - The Ghunter stent features a full visualization design for improved surgical visibility, a curled design for better wall adherence and thrombosis capture, and various mesh sizes to enhance its ability to capture different types of thrombus [4]. - The product has already received a medical device registration certificate from the National Medical Products Administration of China in April 2023 [4]. Group 3: Impact on the Company - The certification signifies that Sino Shenchang has established a quality management system compliant with EU MDR requirements, allowing the stent to meet the latest market entry conditions in the EU [5]. - This approval is expected to positively impact the promotion and sales of the company's products in relevant markets, enhancing the company's market competitiveness and future operations [5].

Core Viewpoint - Microelectrophysiology has received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, which will facilitate entry into the European market and expand overseas revenue [1] Group 1: Product Certification - The company announced that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter have obtained EU MDR certification [1] - This certification is expected to enhance the company's overseas "mapping + ablation" technology matrix [1] Group 2: Market Impact - The entry into the European market is anticipated to increase the company's overseas revenue scale [1] - However, sales in international markets may be affected by uncertainties such as foreign regulatory policies, market environment changes, and exchange rate fluctuations [1] - The company is currently unable to predict the specific impact of these factors on its future business [1]

Group 1 - The core viewpoint of the article highlights that Weili Medical (603309) has seen a stock price increase of 4.18%, closing at 14.94 yuan as of February 6, 2026, compared to 14.34 yuan the previous week [1] - The company achieved a total market capitalization of 4.361 billion yuan, ranking 88th out of 129 in the medical device sector and 3870th out of 5186 in the A-share market [1] - The highest intraday price recorded for Weili Medical during the week was 14.99 yuan, while the lowest was 13.85 yuan [1] Group 2 - Weili Medical announced that multiple products have received EU MDR certification, allowing them to be sold in the European market [1] - The certified products include a range of medical devices such as urinary catheter care kits, drainage bags, puncture guides, and various types of catheters and tubes [1] - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028, confirming compliance with the latest EU medical device regulations [1]

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic coronary intravascular shockwave treatment system, which is designed to treat severely calcified stenosis areas [1][1]. Group 1 - The Lithonic system is intended for use in areas of severe calcification where balloon dilation or stent expansion is insufficient [1][1]. - The system operates by releasing high-pressure shockwaves to pre-treat calcified lesions, utilizing an electrolytic effect in a solution medium [1][1]. - The technology aims to directly modify calcified lesions and reduce the risk of complications associated with traditional treatment methods, such as vascular perforation and no-reflow phenomena [1][1].

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic coronary intravascular shockwave treatment system, which is designed for pre-treatment of severely calcified stenosis, reducing the risk of complications such as vascular perforation and no-reflow [1] Group 1 - The CE certification signifies international recognition of the technology [1] - This certification reinforces the company's technological advantage in the coronary field [1] - The expected positive impact on the company's operational development [1] Group 2 - The sales of medical devices are influenced by market conditions [1] - Investors are advised to exercise caution in their investments [1]

Core Viewpoint - Bluesail Medical's subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for its Lithonic™ coronary intravascular shockwave treatment system, which is designed for pre-treatment of severely calcified stenosis, reducing the risk of complications such as vascular perforation and no-reflow [1] Company Summary - The CE certification signifies international recognition of the technology, reinforcing the company's technological advantage in the coronary field [1] - The expected positive impact on the company's operational development due to this certification [1] Industry Summary - The sales of medical devices are influenced by market conditions, indicating a need for cautious investment from stakeholders [1]

Core Viewpoint - The company NuoVance (688105.SH) has recently obtained CE IVDR certification for six nucleic acid testing kits for respiratory pathogens, allowing sales in EU countries and countries recognizing EU CE certification [1] Group 1 - The six nucleic acid testing kits are specifically designed for respiratory pathogens [1] - The CE IVDR certification is a significant regulatory milestone that enables the company to expand its market reach [1] - The certification allows the company to sell its products in the European Union and other countries that accept EU CE certification [1]

Core Viewpoint - The company has received the highest risk level Class D certification from BSI Group The Netherlands B.V. for its iFlash - HIV Combo test kit, marking a significant achievement in its product certification journey [1] Group 1 - The HIV test kit has successfully passed the IVDR CE certification, which is crucial for market entry in the European Union [1] - This certification covers the full range of eight preoperative chemiluminescent test reagents, bringing the total number of certified products to 229 [1] - The certification is expected to positively impact business promotion, although the exact effect on performance remains unpredictable [1]

Core Viewpoint - The company, Pumen Technology (688389.SH), has received the "Medical Device Single Audit Program" (MDSAP) certification from T V S D America Inc., which enhances its credibility in the medical device market [1] Group 1: Certification Details - The certification covers the design, development, production, and distribution of various medical devices, including negative pressure drainage dressing kits, medical negative pressure suction devices, air wave pressure therapy systems, shock wave therapy devices, and drainage bottles [1] - Additionally, the certification includes the design, development, production, and distribution of in vitro diagnostic medical devices such as electrochemiluminescence analyzers and reagents, hemoglobin analyzers and chromatography columns, glycated hemoglobin analyzers and chromatography columns, and immunofluorescence analyzers [1]

Core Viewpoint - Tianyi Medical has received EU MDR certification for multiple products, indicating compliance with the latest EU medical device regulations, which enhances its market access and sales potential in Europe [1][3]. Trading Information Summary - On November 5, 2025, Tianyi Medical's stock closed at 58.8 yuan, up by 5.0%, with a turnover rate of 12.94% and a trading volume of 37,500 shares, resulting in a transaction value of 216 million yuan [1]. - The net inflow of main funds was 18.84 million yuan, while speculative funds saw a net inflow of 13.12 million yuan; however, retail investors experienced a net outflow of 31.97 million yuan [1][3]. Company Announcement Summary - Tianyi Medical has obtained EU MDR certification for products including Extracorporeal Blood Tubing Set, Oral/Enteral Syringe, Oral/Enteral Syringe with ENFit connector, and Arterial-Venous Fistula Needle Set, with the latter being a newly certified product [1][3]. - The certification, effective from November 4, 2025, and valid until January 5, 2028, signifies that the company's products meet the latest EU regulatory requirements, facilitating their promotion and sales in overseas markets [1].